25 XP   0   0   10

Fagron NV
Buy, Hold or Sell?

Let's analyze Fagron together

I guess you are interested in Fagron NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Fagron NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Fagron NV

I send you an email if I find something interesting about Fagron NV.

Quick analysis of Fagron (30 sec.)










What can you expect buying and holding a share of Fagron? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨1.09
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
‚ā¨6.41
Expected worth in 1 year
‚ā¨9.63
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨4.23
Return On Investment
22.8%

For what price can you sell your share?

Current Price per Share
‚ā¨18.54
Expected price per share
‚ā¨16.55 - ‚ā¨18.92
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Fagron (5 min.)




Live pricePrice per Share (EOD)

‚ā¨18.54

Intrinsic Value Per Share

‚ā¨5.74 - ‚ā¨9.86

Total Value Per Share

‚ā¨12.15 - ‚ā¨16.27

2. Growth of Fagron (5 min.)




Is Fagron growing?

Current yearPrevious yearGrowGrow %
How rich?$510.1m$445.8m$64.3m12.6%

How much money is Fagron making?

Current yearPrevious yearGrowGrow %
Making money$76.9m$75.9m$1m1.3%
Net Profit Margin9.2%10.2%--

How much money comes from the company's main activities?

3. Financial Health of Fagron (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Fagron? (5 min.)

Welcome investor! Fagron's management wants to use your money to grow the business. In return you get a share of Fagron.

What can you expect buying and holding a share of Fagron?

First you should know what it really means to hold a share of Fagron. And how you can make/lose money.

Speculation

The Price per Share of Fagron is ‚ā¨18.54. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Fagron.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Fagron, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨6.41. Based on the TTM, the Book Value Change Per Share is ‚ā¨0.81 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨1.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.25 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Fagron.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps1.055.7%1.055.7%1.045.6%0.904.9%0.281.5%
Usd Book Value Change Per Share0.884.7%0.884.7%1.246.7%0.774.2%0.472.5%
Usd Dividend Per Share0.271.5%0.271.5%0.221.2%0.181.0%0.201.1%
Usd Total Gains Per Share1.156.2%1.156.2%1.467.9%0.955.1%0.673.6%
Usd Price Per Share18.12-18.12-14.48-18.11-17.65-
Price to Earnings Ratio17.19-17.19-13.91-21.29-26.68-
Price-to-Total Gains Ratio15.71-15.71-9.91-30.15-30.97-
Price to Book Ratio2.59-2.59-2.37-3.88-3.97-
Price-to-Total Gains Ratio15.71-15.71-9.91-30.15-30.97-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share20.22714
Number of shares49
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.270.18
Usd Book Value Change Per Share0.880.77
Usd Total Gains Per Share1.150.95
Gains per Quarter (49 shares)56.5246.59
Gains per Year (49 shares)226.10186.37
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
15417321635151176
210734544271302362
3161518668106453548
4214690894141604734
52688631120176755920
6321103613462129061106
73751208157224710581292
84281381179828212091478
94821553202431813601664
105351726225035315111850

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.02.00.080.0%17.03.00.085.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%17.03.00.085.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%18.00.02.090.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%17.03.00.085.0%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Fagron

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Fundamental data was last updated by Penke on 2024-07-07 23:32:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Fagron NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Fagron earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Fagron to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 9.2%¬†means that¬†€0.09 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Fagron NV:

  • The MRQ is 9.2%. The company is making a profit. +1
  • The TTM is 9.2%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ9.2%TTM9.2%0.0%
TTM9.2%YOY10.2%-0.9%
TTM9.2%5Y10.2%-1.0%
5Y10.2%10Y2.7%+7.6%
1.1.2. Return on Assets

Shows how efficient Fagron is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Fagron to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • 7.0% Return on Assets means that¬†Fagron generated¬†€0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Fagron NV:

  • The MRQ is 7.0%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 7.0%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ7.0%TTM7.0%0.0%
TTM7.0%YOY7.2%-0.2%
TTM7.0%5Y7.3%-0.3%
5Y7.3%10Y2.1%+5.3%
1.1.3. Return on Equity

Shows how efficient Fagron is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Fagron to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • 15.2% Return on Equity means Fagron generated €0.15¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Fagron NV:

  • The MRQ is 15.2%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 15.2%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.2%TTM15.2%0.0%
TTM15.2%YOY17.3%-2.1%
TTM15.2%5Y19.6%-4.4%
5Y19.6%10Y14.1%+5.5%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Fagron NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Fagron is operating .

  • Measures how much profit Fagron makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Fagron to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 13.8%¬†means the company generated €0.14 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Fagron NV:

  • The MRQ is 13.8%. The company is operating less efficient.
  • The TTM is 13.8%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ13.8%TTM13.8%0.0%
TTM13.8%YOY14.3%-0.5%
TTM13.8%5Y15.0%-1.2%
5Y15.0%10Y9.9%+5.1%
1.2.2. Operating Ratio

Measures how efficient Fagron is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.86 means that the operating costs are €0.86 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Fagron NV:

  • The MRQ is 0.862. The company is less efficient in keeping operating costs low.
  • The TTM is 0.862. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.862TTM0.8620.000
TTM0.862YOY0.852+0.010
TTM0.8625Y0.845+0.016
5Y0.84510Y0.833+0.013
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Fagron NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Fagron is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.92¬†means the company has €1.92 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Fagron NV:

  • The MRQ is 1.917. The company is able to pay all its short-term debts. +1
  • The TTM is 1.917. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.917TTM1.9170.000
TTM1.917YOY1.860+0.057
TTM1.9175Y1.549+0.368
5Y1.54910Y1.265+0.284
1.3.2. Quick Ratio

Measures if Fagron is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Fagron to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.27¬†means the company can pay off €1.27 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Fagron NV:

  • The MRQ is 1.266. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.266. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.266TTM1.2660.000
TTM1.266YOY1.127+0.140
TTM1.2665Y0.979+0.287
5Y0.97910Y0.772+0.207
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Fagron NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Fagron assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Fagron to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.54¬†means that Fagron assets are¬†financed with 53.6% credit (debt) and the remaining percentage (100% - 53.6%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Fagron NV:

  • The MRQ is 0.536. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.536. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.536TTM0.5360.000
TTM0.536YOY0.579-0.044
TTM0.5365Y0.612-0.076
5Y0.61210Y0.720-0.108
1.4.2. Debt to Equity Ratio

Measures if Fagron is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Fagron to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 116.3% means that company has €1.16 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Fagron NV:

  • The MRQ is 1.163. The company is able to pay all its debts with equity. +1
  • The TTM is 1.163. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.163TTM1.1630.000
TTM1.163YOY1.397-0.234
TTM1.1635Y1.658-0.495
5Y1.65810Y2.290-0.632
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Fagron NV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Fagron generates.

  • Above 15 is considered overpriced but¬†always compare¬†Fagron to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 17.19 means the investor is paying €17.19¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Fagron NV:

  • The EOD is 19.185. Based on the earnings, the company is fair priced.
  • The MRQ is 17.188. Based on the earnings, the company is fair priced.
  • The TTM is 17.188. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD19.185MRQ17.188+1.997
MRQ17.188TTM17.1880.000
TTM17.188YOY13.913+3.274
TTM17.1885Y21.290-4.102
5Y21.29010Y26.679-5.389
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Fagron NV:

  • The EOD is 19.642. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 17.597. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 17.597. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD19.642MRQ17.597+2.045
MRQ17.597TTM17.5970.000
TTM17.597YOY10.648+6.949
TTM17.5975Y18.247-0.650
5Y18.24710Y17.769+0.478
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Fagron is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.59 means the investor is paying €2.59¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Fagron NV:

  • The EOD is 2.894. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.593. Based on the equity, the company is underpriced. +1
  • The TTM is 2.593. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.894MRQ2.593+0.301
MRQ2.593TTM2.5930.000
TTM2.593YOY2.370+0.223
TTM2.5935Y3.877-1.284
5Y3.87710Y3.968-0.090
2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Fagron NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.8070.8070%1.139-29%0.706+14%0.428+89%
Book Value Per Share--6.4066.4060%5.599+14%4.674+37%3.214+99%
Current Ratio--1.9171.9170%1.860+3%1.549+24%1.265+52%
Debt To Asset Ratio--0.5360.5360%0.579-8%0.612-12%0.720-26%
Debt To Equity Ratio--1.1631.1630%1.397-17%1.658-30%2.290-49%
Dividend Per Share--0.2500.2500%0.200+25%0.165+52%0.185+35%
Eps--0.9660.9660%0.954+1%0.827+17%0.252+283%
Free Cash Flow Per Share--0.9440.9440%1.246-24%0.951-1%0.910+4%
Free Cash Flow To Equity Per Share--0.1630.1630%1.436-89%0.506-68%0.512-68%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--9.865--------
Intrinsic Value_10Y_min--5.743--------
Intrinsic Value_1Y_max--0.995--------
Intrinsic Value_1Y_min--0.834--------
Intrinsic Value_3Y_max--2.984--------
Intrinsic Value_3Y_min--2.296--------
Intrinsic Value_5Y_max--4.967--------
Intrinsic Value_5Y_min--3.519--------
Market Cap1353177051.840+10%1212530000.0001212530000.0000%968536109.920+25%1211845834.944+0%1181042870.966+3%
Net Profit Margin--0.0920.0920%0.102-9%0.102-10%0.027+244%
Operating Margin--0.1380.1380%0.143-3%0.150-8%0.099+39%
Operating Ratio--0.8620.8620%0.852+1%0.845+2%0.833+3%
Pb Ratio2.894+10%2.5932.5930%2.370+9%3.877-33%3.968-35%
Pe Ratio19.185+10%17.18817.1880%13.913+24%21.290-19%26.679-36%
Price Per Share18.540+10%16.61016.6100%13.270+25%16.602+0%16.181+3%
Price To Free Cash Flow Ratio19.642+10%17.59717.5970%10.648+65%18.247-4%17.769-1%
Price To Total Gains Ratio17.535+10%15.70915.7090%9.910+59%30.152-48%30.967-49%
Quick Ratio--1.2661.2660%1.127+12%0.979+29%0.772+64%
Return On Assets--0.0700.0700%0.072-2%0.073-4%0.021+239%
Return On Equity--0.1520.1520%0.173-12%0.196-22%0.141+8%
Total Gains Per Share--1.0571.0570%1.339-21%0.872+21%0.613+72%
Usd Book Value--510179966.000510179966.0000%445817512.000+14%372245708.800+37%255907578.400+99%
Usd Book Value Change Per Share--0.8810.8810%1.243-29%0.771+14%0.467+89%
Usd Book Value Per Share--6.9896.9890%6.108+14%5.100+37%3.506+99%
Usd Dividend Per Share--0.2730.2730%0.218+25%0.180+52%0.202+35%
Usd Eps--1.0541.0540%1.041+1%0.902+17%0.275+283%
Usd Free Cash Flow--75176446.00075176446.0000%99238451.000-24%75734601.600-1%72432908.300+4%
Usd Free Cash Flow Per Share--1.0301.0300%1.360-24%1.038-1%0.992+4%
Usd Free Cash Flow To Equity Per Share--0.1780.1780%1.567-89%0.552-68%0.559-68%
Usd Market Cap1476316163.557+10%1322870230.0001322870230.0000%1056672895.923+25%1322123805.924+0%1288517772.224+3%
Usd Price Per Share20.227+10%18.12218.1220%14.478+25%18.113+0%17.653+3%
Usd Profit--76966777.00076966777.0000%75946692.000+1%69049608.200+11%21703372.100+255%
Usd Revenue--832423181.000832423181.0000%746114171.000+12%678895697.200+23%584977835.000+42%
Usd Total Gains Per Share--1.1541.1540%1.461-21%0.951+21%0.669+72%
 EOD+4 -4MRQTTM+0 -0YOY+17 -185Y+23 -1210Y+30 -5

3.2. Fundamental Score

Let's check the fundamental score of Fagron NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1519.185
Price to Book Ratio (EOD)Between0-12.894
Net Profit Margin (MRQ)Greater than00.092
Operating Margin (MRQ)Greater than00.138
Quick Ratio (MRQ)Greater than11.266
Current Ratio (MRQ)Greater than11.917
Debt to Asset Ratio (MRQ)Less than10.536
Debt to Equity Ratio (MRQ)Less than11.163
Return on Equity (MRQ)Greater than0.150.152
Return on Assets (MRQ)Greater than0.050.070
Total7/10 (70.0%)

3.3. Technical Score

Let's check the technical score of Fagron NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.427
Ma 20Greater thanMa 5018.038
Ma 50Greater thanMa 10018.293
Ma 100Greater thanMa 20017.796
OpenGreater thanClose18.580
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Short-term Investments  -3,3392,013-1,326-385-1,711-15,297-17,00821,2764,268



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets1,006,954
Total Liabilities539,328
Total Stockholder Equity463,754
 As reported
Total Liabilities 539,328
Total Stockholder Equity+ 463,754
Total Assets = 1,006,954

Assets

Total Assets1,006,954
Total Current Assets335,901
Long-term Assets671,053
Total Current Assets
Cash And Cash Equivalents 133,008
Short-term Investments 4,268
Net Receivables 84,688
Inventory 113,938
Total Current Assets  (as reported)335,901
Total Current Assets  (calculated)335,902
+/- 1
Long-term Assets
Property Plant Equipment 147,935
Goodwill 434,361
Intangible Assets 48,560
Other Assets 0
Long-term Assets  (as reported)671,053
Long-term Assets  (calculated)630,856
+/- 40,197

Liabilities & Shareholders' Equity

Total Current Liabilities175,258
Long-term Liabilities364,070
Total Stockholder Equity463,754
Total Current Liabilities
Short-term Debt 9,678
Accounts payable 104,932
Other Current Liabilities 60,566
Total Current Liabilities  (as reported)175,258
Total Current Liabilities  (calculated)175,176
+/- 82
Long-term Liabilities
Long term Debt 325,039
Capital Lease Obligations 41,704
Long-term Liabilities  (as reported)364,070
Long-term Liabilities  (calculated)366,743
+/- 2,673
Total Stockholder Equity
Common Stock524,531
Retained Earnings 206,273
Accumulated Other Comprehensive Income -245,970
Other Stockholders Equity -21,080
Total Stockholder Equity (as reported)463,754
Total Stockholder Equity (calculated)463,754
+/-0
Other
Capital Stock524,531
Cash and Short Term Investments 133,008
Common Stock Shares Outstanding 73,000
Current Deferred Revenue82
Liabilities and Stockholders Equity 1,006,954
Net Debt 233,735
Net Invested Capital 788,761
Net Working Capital 160,643
Property Plant and Equipment Gross 278,873
Short Long Term Debt Total 366,743



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-31
> Total Assets 
273,194
272,038
285,458
347,467
417,733
472,160
573,592
680,232
748,894
804,693
973,752
689,381
868,053
594,047
682,772
801,240
752,826
800,421
971,010
1,006,954
1,006,954971,010800,421752,826801,240682,772594,047868,053689,381973,752804,693748,894680,232573,592472,160417,733347,467285,458272,038273,194
   > Total Current Assets 
120,847
112,232
112,446
156,096
163,518
182,628
217,782
233,856
237,607
236,536
228,114
187,846
412,346
166,430
199,726
239,189
221,883
233,711
318,010
335,901
335,901318,010233,711221,883239,189199,726166,430412,346187,846228,114236,536237,607233,856217,782182,628163,518156,096112,446112,232120,847
       Cash And Cash Equivalents 
5,072
4,707
2,532
27,789
18,503
34,284
51,186
69,850
72,353
128,871
108,552
75,474
74,962
60,771
77,579
106,684
84,248
70,647
125,337
133,008
133,008125,33770,64784,248106,68477,57960,77174,96275,474108,552128,87172,35369,85051,18634,28418,50327,7892,5324,7075,072
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
-4,319
-852
-1,018
-1,215
-3,339
-1,326
-1,711
-17,008
4,268
4,268-17,008-1,711-1,326-3,339-1,215-1,018-852-4,31900000000000
       Net Receivables 
51,536
48,178
48,759
57,129
65,975
70,170
86,303
0
79,292
29,611
54,380
45,121
56,708
42,794
47,489
55,026
57,842
72,232
84,336
84,688
84,68884,33672,23257,84255,02647,48942,79456,70845,12154,38029,61179,292086,30370,17065,97557,12948,75948,17851,536
       Inventory 
56,020
51,438
50,062
56,521
62,808
60,771
66,059
76,643
85,963
58,917
65,181
67,251
60,054
62,865
74,658
77,479
79,794
90,834
108,337
113,938
113,938108,33790,83479,79477,47974,65862,86560,05467,25165,18158,91785,96376,64366,05960,77162,80856,52150,06251,43856,020
       Other Current Assets 
8,219
7,909
11,093
14,657
16,232
17,403
14,234
87,363
-1
48,748
1
45,121
277,330
42,794
47,489
10,438
-1
-2
23,614
4,267
4,26723,614-2-110,43847,48942,794277,33045,121148,748-187,36314,23417,40316,23214,65711,0937,9098,219
   > Long-term Assets 
152,347
159,806
173,012
191,371
254,215
289,532
355,810
446,376
511,288
568,157
745,637
501,536
455,706
427,617
483,049
562,049
530,941
566,710
653,000
671,053
671,053653,000566,710530,941562,049483,049427,617455,706501,536745,637568,157511,288446,376355,810289,532254,215191,371173,012159,806152,347
       Property Plant Equipment 
16,287
16,844
16,397
21,195
34,473
38,631
48,862
57,150
59,256
47,455
59,968
71,133
72,878
69,535
73,440
121,207
118,624
128,626
143,596
147,935
147,935143,596128,626118,624121,20773,44069,53572,87871,13359,96847,45559,25657,15048,86238,63134,47321,19516,39716,84416,287
       Goodwill 
0
0
0
0
0
0
0
0
382,481
371,630
522,069
373,608
297,785
322,838
365,136
389,326
364,654
380,410
429,768
434,361
434,361429,768380,410364,654389,326365,136322,838297,785373,608522,069371,630382,48100000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
867
1,595
1,540
1,270
1,214
943
4,287
0
0
0
0
00004,2879431,2141,2701,5401,595867000000000
       Intangible Assets 
0
0
0
155,662
201,126
229,455
284,498
367,069
35,385
28,956
53,184
36,994
73,221
21,657
26,253
28,810
24,512
30,666
33,633
48,560
48,56033,63330,66624,51228,81026,25321,65773,22136,99453,18428,95635,385367,069284,498229,455201,126155,662000
       Long-term Assets Other 
667
627
667
642
957
1,013
847
970
1,870
90,957
86,458
5,859
1
2,232
1
-1
2,340
-1
21,218
-1
-121,218-12,340-112,23215,85986,45890,9571,8709708471,013957642667627667
> Total Liabilities 
170,654
189,171
190,576
169,242
232,203
275,808
365,470
459,780
503,510
649,526
816,809
754,155
715,179
409,166
473,056
554,799
495,007
474,955
562,378
539,328
539,328562,378474,955495,007554,799473,056409,166715,179754,155816,809649,526503,510459,780365,470275,808232,203169,242190,576189,171170,654
   > Total Current Liabilities 
143,458
174,019
132,419
157,072
100,955
118,711
139,723
447,045
188,371
230,364
220,938
727,090
406,053
108,241
187,806
191,771
200,256
145,062
171,009
175,258
175,258171,009145,062200,256191,771187,806108,241406,053727,090220,938230,364188,371447,045139,723118,711100,955157,072132,419174,019143,458
       Short-term Debt 
75,855
100,160
53,618
72,917
0
4,876
2,315
1,935
4,865
55,004
5,710
594,908
290,559
13,451
63,955
40,723
71,090
14,318
19,009
9,678
9,67819,00914,31871,09040,72363,95513,451290,559594,9085,71055,0044,8651,9352,3154,876072,91753,618100,16075,855
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
426,165
5,349
596,666
290,475
13,386
63,889
34,119
64,440
6,796
9,461
0
09,4616,79664,44034,11963,88913,386290,475596,6665,349426,165000000000
       Accounts payable 
46,159
49,058
49,525
56,943
64,624
67,605
80,845
94,194
97,641
55,551
57,440
63,043
53,163
58,950
63,918
77,303
72,252
83,660
97,856
104,932
104,93297,85683,66072,25277,30363,91858,95053,16363,04357,44055,55197,64194,19480,84567,60564,62456,94349,52549,05846,159
       Other Current Liabilities 
1
1
-1
9,159
36,331
46,230
29,757
313,578
43,753
83,076
108,337
26,657
7,645
2,774
23,072
3,919
4,167
1,266
54,103
60,566
60,56654,1031,2664,1673,91923,0722,7747,64526,657108,33783,07643,753313,57829,75746,23036,3319,159-111
   > Long-term Liabilities 
27,196
15,152
58,157
12,170
131,248
157,097
225,747
12,735
315,139
419,162
595,871
27,065
309,126
300,925
285,250
363,028
294,751
329,893
391,369
364,070
364,070391,369329,893294,751363,028285,250300,925309,12627,065595,871419,162315,13912,735225,747157,097131,24812,17058,15715,15227,196
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
290,433
283,518
265,917
350,808
284,448
321,270
0
0
00321,270284,448350,808265,917283,518290,433000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
17,936
21,107
22,653
18,692
17,407
19,201
11,769
10,303
8,623
9,113
0
09,1138,62310,30311,76919,20117,40718,69222,65321,10717,936000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
23,108
2,996
2,301
3,797
3,870
5,132
6,265
6,205
7,090
0
0
007,0906,2056,2655,1323,8703,7972,3012,99623,108000000000
> Total Stockholder Equity
102,540
82,867
94,882
178,225
181,562
194,306
205,838
216,672
241,631
151,552
154,626
-67,474
149,791
181,398
205,841
242,028
253,107
320,105
402,655
463,754
463,754402,655320,105253,107242,028205,841181,398149,791-67,474154,626151,552241,631216,672205,838194,306181,562178,22594,88282,867102,540
   Common Stock
0
0
0
0
0
0
0
317,527
318,134
318,927
319,660
345,760
561,852
507,670
507,670
510,142
513,987
520,785
521,238
524,531
524,531521,238520,785513,987510,142507,670507,670561,852345,760319,660318,927318,134317,5270000000
   Retained Earnings Total Equity00000000000000000000
   Accumulated Other Comprehensive Income -245,970-248,191-277,154-289,397-242,805-72,545-60,780-62,807-58,607-47,977-41,085-44,057-41,586-34,302-29,60600-24,884-24,415-23,337
   Capital Surplus 00000000000000000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
125,877
107,282
119,766
178,225
181,562
223,912
240,140
-166,501
-168,356
-211,256
-196,040
-200,126
-174,191
-191,269
-190,363
-261,628
-308,220
-295,977
-268,900
-21,080
-21,080-268,900-295,977-308,220-261,628-190,363-191,269-174,191-200,126-196,040-211,256-168,356-166,501240,140223,912181,562178,225119,766107,282125,877



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.